01 January 1999
Disturbed cardiac rhythm as a manifestation of cardiotoxicity of individual doses of anthracycline cytostatics
Vladimir KovcinMed Sci Monit 1999; 5(1): CR32-39 :: ID: 505204
Abstract
Anthracyclines are cytotoxic drugs featuring cardiotoxicity as one of most prominent undesirable effects, which occurs in both its acute or cumulative from. The acute from of cardiotoxicity has been subject of much less concern although some sudden deaths have been reported during anthracycline administration (Wortman et al. Cancer 44; 1979). The present study involved 36 patients with soft tissue sarcomata, 28 with non-Hodgkin's lymphomas, 23 with nasopharyngeal carcinomas, 5 with carcinoma of the lungs, and 7 breast carcinoma patients (99 patients in total) who were treated with anthracyclines. Zorubicin was given to 40 patients, doxorubicin to 21, epidoxorubicin to 20, adn mitoxantron to 18 patients. Control groups were made of 29 patients who did not receive any anthracyclines and those who were treated with anthracyclines for the first time. In addition, as a third group, each patient was his/hers own control. All patients were subject to continuing ECG monitoring by using a Delmar Avionics Stratscan holter ECG monitor. In the course of intravenous infusion of anthracyclines, irregularities of heartbeat occurred in the form of sinus tachycardia and atrial (AEBs) and ventricular ectopic beats (VEBs). In relation to the control, the number of VEBs increased to level III of the Lown's scale while administering zorubicin, and then receded after the infusion. The number of AEBs remained steady or even increased for a certain while after administration of the drug. These irregularities were most prominent during the first administration of anthracycline. However, all registered changes are reversible and neither make a hindrance to therapy, nor necessitate cessation of anthracycline administration. A sporadic occurrence of VEBs at level III according to the Lown's scale point out to a possible occurrence of more severe rhythm disorders.
Keywords: doses, mode of administration, Holter-ECG, cardiotoxicity, Anthracyclines
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952